IL89031A - Drugs containing benzamide for the treatment of thought disorders or for their prevention and preparation - Google Patents

Drugs containing benzamide for the treatment of thought disorders or for their prevention and preparation

Info

Publication number
IL89031A
IL89031A IL8903189A IL8903189A IL89031A IL 89031 A IL89031 A IL 89031A IL 8903189 A IL8903189 A IL 8903189A IL 8903189 A IL8903189 A IL 8903189A IL 89031 A IL89031 A IL 89031A
Authority
IL
Israel
Prior art keywords
treatment
dementia
moclobemide
cognitive
prevention
Prior art date
Application number
IL8903189A
Other languages
English (en)
Hebrew (he)
Other versions
IL89031A0 (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL89031A0 publication Critical patent/IL89031A0/xx
Publication of IL89031A publication Critical patent/IL89031A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL8903189A 1988-01-28 1989-01-23 Drugs containing benzamide for the treatment of thought disorders or for their prevention and preparation IL89031A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH29888 1988-01-28

Publications (2)

Publication Number Publication Date
IL89031A0 IL89031A0 (en) 1989-08-15
IL89031A true IL89031A (en) 1995-07-31

Family

ID=4183804

Family Applications (1)

Application Number Title Priority Date Filing Date
IL8903189A IL89031A (en) 1988-01-28 1989-01-23 Drugs containing benzamide for the treatment of thought disorders or for their prevention and preparation

Country Status (15)

Country Link
US (1) US4906626A (fr)
EP (1) EP0326023B1 (fr)
JP (1) JPH07116043B2 (fr)
KR (1) KR960016203B1 (fr)
AT (1) ATE113207T1 (fr)
AU (1) AU620584B2 (fr)
CA (1) CA1332151C (fr)
DE (1) DE58908544D1 (fr)
DK (1) DK171094B1 (fr)
ES (1) ES2063060T3 (fr)
HU (1) HU203042B (fr)
IE (1) IE65409B1 (fr)
IL (1) IL89031A (fr)
PH (1) PH26030A (fr)
ZA (1) ZA89523B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0559297B1 (fr) * 1986-12-17 1997-05-07 Glaxo Group Limited Utilisation des dérivés hétérocycliques pour la manufacture des médicaments
FR2645742A1 (fr) * 1989-04-12 1990-10-19 Delagrange Laboratoires Application de derives de 2-methoxy 4-(4,5-dihydro 2-imidazolyl (ou 2-oxazolyl) amino) 5-chloro benzamide dans le traitement des troubles de la fonction cognitive
JP3172202B2 (ja) * 1990-11-29 2001-06-04 エフ．ホフマン−ラ ロシュ アーゲー 不安の障害の処置剤
US6951884B2 (en) * 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
AU2004283452A1 (en) * 2003-10-23 2005-05-06 F. Hoffmann-La Roche Ag Benzazepine derivatives as MAO-B inhibitors
WO2005053703A1 (fr) * 2003-12-02 2005-06-16 Leslie James Sheldon Polytherapie contre la demence, la depression et l'apathie
CA2628074C (fr) 2005-10-25 2014-01-14 Shionogi & Co., Ltd. Derive aminodihydrothiazine
WO2008133273A1 (fr) * 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Composition pharmaceutique pour le traitement de la maladie d'alzheimer
KR20100017255A (ko) * 2007-04-24 2010-02-16 시오노기 앤드 컴파니, 리미티드 환식기로 치환된 아미노다이하이드로싸이아진 유도체
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
US8703785B2 (en) * 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
EP2634186A4 (fr) 2010-10-29 2014-03-26 Shionogi & Co Dérivé de naphtyridine
EP2703399A4 (fr) 2011-04-26 2014-10-15 Shionogi & Co Dérivé d'oxazine et inhibiteur de bace 1 le contenant
WO2014065434A1 (fr) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1
US10599006B2 (en) 2016-04-12 2020-03-24 E-Vision Smart Optics, Inc. Electro-active lenses with raised resistive bridges
ES2973138T3 (es) 2016-04-12 2024-06-18 E Vision Smart Optics Inc Lentes electroactivas con puentes resistivos elevados

Also Published As

Publication number Publication date
DK36889D0 (da) 1989-01-27
DK171094B1 (da) 1996-06-03
JPH01224318A (ja) 1989-09-07
DE58908544D1 (de) 1994-12-01
HUT50042A (en) 1989-12-28
CA1332151C (fr) 1994-09-27
JPH07116043B2 (ja) 1995-12-13
KR960016203B1 (ko) 1996-12-06
PH26030A (en) 1992-01-29
AU620584B2 (en) 1992-02-20
US4906626A (en) 1990-03-06
DK36889A (da) 1989-07-29
AU2883689A (en) 1989-08-03
EP0326023A2 (fr) 1989-08-02
EP0326023A3 (en) 1990-09-05
HU203042B (en) 1991-05-28
IE890273L (en) 1989-07-28
ES2063060T3 (es) 1995-01-01
ZA89523B (en) 1989-09-27
IL89031A0 (en) 1989-08-15
EP0326023B1 (fr) 1994-10-26
IE65409B1 (en) 1995-10-18
ATE113207T1 (de) 1994-11-15
KR890011589A (ko) 1989-08-21

Similar Documents

Publication Publication Date Title
US4906626A (en) Method of use for treatment or prevention of cognitive disorders
RU2334514C1 (ru) СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
JPS591412A (ja) 脳血管不全症処置用固形製剤
CN109846884A (zh) 用tor激酶抑制剂治疗癌症
TWI549678B (zh) ４－胺基吡啶於改善具有脫髓鞘及其他神經系統狀況之患者的神經認知及／或神經精神缺陷之用途
CN104884053B (zh) 用于改善记忆表现的益智组合物
DK169656B1 (da) Anvendelse af adenosinderivater til fremstilling af et lægemiddel med virkning mod demens
Towse Cinnarizine—a labyrinthine sedative
US3459850A (en) Sustained-release tablets,a process and a composition for their preparation
MXPA05009850A (es) Metodo para tratar el deterioro cognitivo leve y para prevenir o atrasar la enfermedad de alzheimer.
Boner et al. Efficacy and safety of loratadine suspension in the treatment of children with allergic rhinitis
JPH04327532A (ja) 活動過剰を伴う注意力欠乏疾患の治療に使用する医薬製剤
US4719212A (en) Therapeutic agent for memory disturbance
NZ188098A (en) Antithrombotic compositions based on synergistic combinations of 2,6-bis-(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine and 1,2-diphenyl-4-(2-phenylsulphinylethyl)pyrazolidine-3,5-dione
Miyamoto et al. Effects of a sustained release formulation of thyrotropin-releasing hormone on behavioral abnormalities in senescence-accelerated mice
CA1201656A (fr) Produits pharmaceutiques, leur composition et leur emploi
US3740433A (en) Anti-anxiety composition and method of use
US4315937A (en) Ergots and their use in treating minimal brain dysfunction
RU2277096C2 (ru) Средства против слабоумия, содержащие производное 2-арил-8-оксодигидропурина в качестве активного ингредиента
AU634149B2 (en) Pain-killer
US11752141B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
JPWO2012036191A1 (ja) 脳機能改善用組成物および脳機能を改善する方法
Costall et al. 5-HT3 receptor antagonists in the treatment of cognitive disorders
Toma et al. Incidence of Yersinia enterocolitica and Y. pseudotuberculosis infections in Canada; 1975 semiannual report.
AU4279599A (en) Use of an nk-1 receptor antagonist for treating cognitive disorders

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed